Safety of high efficacy therapies in older people with Multiple Sclerosis: A real-world evidence study
Authors:
- 19 August 2024
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 90, 105830
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing–remitting multiple sclerosis patients: a monocentric longitudinal observational studyJournal of Neurology, 2023
- Rituximab for the treatment of multiple sclerosis: a reviewJournal of Neurology, 2021
- Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple SclerosisJAMA Neurology, 2019
- Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying DrugsCNS Drugs, 2018
- Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammationJournal of Neurology, 2018
- Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathyJournal of NeuroVirology, 2017
- Immunosenescence: the Role of Aging in the Predisposition to Neuro-Infectious Complications Arising from the Treatment of Multiple SclerosisCurrent Neurology and Neuroscience Reports, 2017
- High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991–2010)Journal of Neurology, 2015
- Revised estimate of the prevalence of multiple sclerosis in the united statesAnnals of Neurology, 1992
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987